DocGo Inc. Under Legal Investigation
San Francisco, July 17, 2025 - DocGo Inc. (NASDAQ: DCGO) is facing a significant legal challenge as Schubert Jonckheer & Kolbe LLP has announced an investigation into potential wrongdoing by the company's executives. Allegations are surfacing regarding false claims about the educational background of former CEO Anthony Capone and the company's purported business operations, specifically related to enrolling migrants in New York's Medicaid program and its relationship with UnitedHealthcare.
On March 28, 2025, a ruling by Judge Katherine Polk Failla of the U.S. District Court for the Southern District of New York permitted key aspects of a securities fraud lawsuit against DocGo and Mr. Capone to proceed. This lawsuit contends that between April 2022 and September 2023, DocGo misrepresented vital information, misleading investors by falsely claiming that Mr. Capone held a graduate degree in computer science.
The suit claims that these misleading statements inflated DocGo's stock prices, thus harming investors when the truth came to light. Judge Failla referred to multiple statements made by the defendants as “indisputably false” and highlighted the intent to defraud. The timing was particularly concerning since, during the period of manipulation, insiders sold off approximately $4 million worth of stock, raising substantial red flags regarding corporate governance and ethical practices.
The situation worsened in September 2023 when it was revealed that Mr. Capone never graduated from any graduate program, DocGo failed to enroll anyone in Medicaid, and the rumored partnership with UnitedHealthcare was non-existent. Following this disclosure, DocGo’s stock plummeted by 25%, dramatically affecting shareholders.
Schubert Jonckheer & Kolbe LLP is reaching out to investors in DocGo, encouraging them to explore their legal options and consider potential claims against the company’s directors and officers. In cases where corporate leaders fail to uphold their fiduciary duties, shareholders have the right to hold them accountable through various legal avenues.
Recent reports have echoed the fact that misinformation and misleading practices are increasingly under scrutiny, especially in the fast-evolving tech and healthcare sectors. The onus is now on DocGo to clarify its position and rectify any potential missteps taken by its leadership. As this investigation unfolds, current and prospective investors are advised to stay informed and consider their positions carefully.
For more information regarding your legal rights as a DocGo shareholder, you can visit
this link or contact Schubert Jonckheer & Kolbe LLP directly.
The implications of this case may resonate across the healthcare and technology investment landscapes, serving as a reminder of the importance of accountability in corporate governance. Investors are encouraged to be vigilant in protecting their interests as this scenario unfolds, demonstrating the delicate balance of trust and information in the stock market.
In conclusion, as this investigation progresses, attention will remain focused on how DocGo chooses to address these allegations and what repercussions may follow in the investments community. Ethical business practices and transparency will be pivotal in restoring investor confidence going forward.